HUP0102257A2 - Módosított K-vitamin-dependens polipeptidek - Google Patents

Módosított K-vitamin-dependens polipeptidek

Info

Publication number
HUP0102257A2
HUP0102257A2 HU0102257A HUP0102257A HUP0102257A2 HU P0102257 A2 HUP0102257 A2 HU P0102257A2 HU 0102257 A HU0102257 A HU 0102257A HU P0102257 A HUP0102257 A HU P0102257A HU P0102257 A2 HUP0102257 A2 HU P0102257A2
Authority
HU
Hungary
Prior art keywords
vitamin
dependent polypeptide
subject
dependent
nucleic acid
Prior art date
Application number
HU0102257A
Other languages
English (en)
Inventor
Gary L. Nelsestuen
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Publication of HUP0102257A2 publication Critical patent/HUP0102257A2/hu
Publication of HUP0102257A3 publication Critical patent/HUP0102257A3/hu
Publication of HU225993B1 publication Critical patent/HU225993B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

A találmány tárgya K-vitamin-dependens polipeptid, amely olyanmódosított GLA-domént tartalmaz, amely a polipeptid membránkötődésiaffinitását - egy megfelelő, természetes K-vitamin-dependenspolipeptidéhez viszonyítva - növeli, és amely a 11., 12., 29. vagy 34.pozícióban legalább egy aminosav-szubsztitúciót hordoz. Szintén atalálmány tárgyát képezi a találmány szerinti, módosított GLA-doménttartalmazó K-vitamin-dependens polipeptidet kódoló izolált nukleinsav;az ilyen nukleinsavat hordozó emlőseredetű gazdasejt; valamint a K-vitamin-dependens polipeptid hatásos mennyiségét tartalmazógyógyászati készítmény. A találmány tárgyát képezi továbbá a találmányszerinti K-vitamin-dependens polipeptid alkalmazása véralvadásirendellenesség kezelésére alkalmas gyógyszer előállítására. Ó
HU0102257A 1997-10-23 1998-10-20 Modified vitamin k-dependent polypeptides HU225993B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides
PCT/US1998/022152 WO1999020767A1 (en) 1997-10-23 1998-10-20 Modified vitamin k-dependent polypeptides

Publications (3)

Publication Number Publication Date
HUP0102257A2 true HUP0102257A2 (hu) 2001-09-28
HUP0102257A3 HUP0102257A3 (en) 2003-09-29
HU225993B1 HU225993B1 (en) 2008-02-28

Family

ID=25497114

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102257A HU225993B1 (en) 1997-10-23 1998-10-20 Modified vitamin k-dependent polypeptides

Country Status (30)

Country Link
US (1) US6017882A (hu)
EP (2) EP1676919B1 (hu)
JP (1) JP4276379B2 (hu)
KR (1) KR20010031370A (hu)
CN (1) CN1246462C (hu)
AP (1) AP2000001811A0 (hu)
AR (2) AR020048A1 (hu)
AT (1) ATE390486T1 (hu)
AU (1) AU749279C (hu)
BR (1) BR9814611A (hu)
CA (1) CA2307175C (hu)
DE (1) DE69839313T2 (hu)
DK (1) DK1090128T3 (hu)
EA (1) EA200000449A1 (hu)
ES (2) ES2303362T3 (hu)
HR (1) HRP20000234A2 (hu)
HU (1) HU225993B1 (hu)
ID (1) ID26330A (hu)
IL (1) IL135603A0 (hu)
IS (1) IS5449A (hu)
MY (1) MY136336A (hu)
NO (1) NO20002025L (hu)
NZ (1) NZ504114A (hu)
PL (1) PL194194B1 (hu)
PT (1) PT1090128E (hu)
SG (1) SG105547A1 (hu)
TR (1) TR200001105T2 (hu)
TW (1) TW587081B (hu)
WO (1) WO1999020767A1 (hu)
ZA (1) ZA989597B (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
ES2234807T3 (es) 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US6828306B2 (en) * 2000-07-31 2004-12-07 Ottawa Heart Institute Research Corporation Charged lipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
CA2440092A1 (en) * 2001-03-02 2002-09-12 T.A.C. Thrombosis And Coagulation Ab Protein c variants
JP2005518801A (ja) * 2002-03-01 2005-06-30 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・アクテイエボラーク 組換えプロテインｃバリアント
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
PT1499719E (pt) 2002-04-30 2011-02-09 Bayer Healthcare Llc Variantes polipeptídicas do factor vii ou viia
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
WO2004083421A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases
ATE431403T1 (de) 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
EP2275432A1 (en) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration of factor VII solutions to remove virus
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
KR101364001B1 (ko) 2004-12-23 2014-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 관심있는 비타민 ｋ-의존성 단백질을 포함한 조성물 중의단백질 오염물질의 양의 감소
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2007006808A1 (en) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
CN101268185B (zh) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化
US20090055942A1 (en) 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
CA2673260A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
SG174077A1 (en) 2007-04-13 2011-09-29 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
PT2235197T (pt) 2007-12-27 2017-10-11 Baxalta Inc Processos para cultura de células
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
AU2010258752B2 (en) 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2514760B1 (en) * 2009-12-14 2015-10-21 National University Corporation Hokkaido University Peptides imparting cell permeability to lipid membrane structure
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI882746A (fi) * 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Also Published As

Publication number Publication date
NO20002025L (no) 2000-06-19
ID26330A (id) 2000-12-14
EP1090128A1 (en) 2001-04-11
NZ504114A (en) 2002-10-25
SG105547A1 (en) 2004-08-27
CA2307175C (en) 2009-04-14
AP2000001811A0 (en) 2000-06-30
IS5449A (is) 2000-04-14
EA200000449A1 (ru) 2000-12-25
AU749279B2 (en) 2002-06-20
PT1090128E (pt) 2008-04-17
DE69839313D1 (de) 2008-05-08
TR200001105T2 (tr) 2000-09-21
JP4276379B2 (ja) 2009-06-10
HUP0102257A3 (en) 2003-09-29
IL135603A0 (en) 2001-05-20
JP2001520042A (ja) 2001-10-30
CA2307175A1 (en) 1999-04-29
PL194194B1 (pl) 2007-05-31
BR9814611A (pt) 2000-10-03
EP1676919B1 (en) 2014-07-23
CN1246462C (zh) 2006-03-22
NO20002025D0 (no) 2000-04-18
ES2303362T3 (es) 2008-08-01
TW587081B (en) 2004-05-11
DE69839313T2 (de) 2009-04-16
EP1676919A1 (en) 2006-07-05
DK1090128T3 (da) 2008-06-23
PL340284A1 (en) 2001-01-29
CN1283231A (zh) 2001-02-07
AU749279C (en) 2004-09-16
AR035786A2 (es) 2004-07-14
HRP20000234A2 (en) 2001-08-31
US6017882A (en) 2000-01-25
WO1999020767A1 (en) 1999-04-29
AU2702499A (en) 1999-05-10
HU225993B1 (en) 2008-02-28
AR020048A1 (es) 2002-04-10
KR20010031370A (ko) 2001-04-16
ES2496104T3 (es) 2014-09-18
MY136336A (en) 2008-09-30
ATE390486T1 (de) 2008-04-15
EP1090128B1 (en) 2008-03-26
ZA989597B (en) 1999-04-23

Similar Documents

Publication Publication Date Title
HUP0102257A2 (hu) Módosított K-vitamin-dependens polipeptidek
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
HUP0000302A2 (hu) OB fúziós protein készítmények és módszerek
HUP0101948A2 (hu) Il-2-szelektív agonisták és antagonisták
HUP0103758A2 (hu) Neurotróf faktorok
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
AU5911499A (en) Leptin induced genes
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
ZA977582B (en) Homocysteine desulphurase.
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
DE3884680D1 (de) Äusseres Membranprotein F von Pseudomonas aeruginosa.
WO2001088085A3 (en) Novel bee venom polypeptides and methods of use thereof
HUP0000248A2 (hu) Nagy affinitású interleukin-4 muteinek
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
WO2000042166A3 (en) Methods and compositions for monitoring cellular processing of epitope-tagged beta-amyloid precursor protein
CA2002833A1 (en) Interferon-gamma binding proteins
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
NO985742L (no) IL-1/TNF-<alfa>-aktivert kinase (ITAK) og fremgangsmÕter for fremstilling og anvendelse av denne
DE69529235D1 (de) Menschliche dnase i varianten
DE60115039D1 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees